WO2018066394A1 - Composition pour l'assouplissement des muscles - Google Patents

Composition pour l'assouplissement des muscles Download PDF

Info

Publication number
WO2018066394A1
WO2018066394A1 PCT/JP2017/034436 JP2017034436W WO2018066394A1 WO 2018066394 A1 WO2018066394 A1 WO 2018066394A1 JP 2017034436 W JP2017034436 W JP 2017034436W WO 2018066394 A1 WO2018066394 A1 WO 2018066394A1
Authority
WO
WIPO (PCT)
Prior art keywords
fatty acid
acid
composition
muscle
fish oil
Prior art date
Application number
PCT/JP2017/034436
Other languages
English (en)
Japanese (ja)
Inventor
賢一 柳本
韓　力
二功 川端
Original Assignee
日本水産株式会社
国立大学法人 九州大学
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 日本水産株式会社, 国立大学法人 九州大学 filed Critical 日本水産株式会社
Priority to JP2018543844A priority Critical patent/JPWO2018066394A1/ja
Publication of WO2018066394A1 publication Critical patent/WO2018066394A1/fr

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/115—Fatty acids or derivatives thereof; Fats or oils
    • A23L33/12—Fatty acids or derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/23—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms
    • A61K31/232—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms having three or more double bonds, e.g. etretinate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/56—Materials from animals other than mammals
    • A61K35/60—Fish, e.g. seahorses; Fish eggs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/56—Materials from animals other than mammals
    • A61K35/612—Crustaceans, e.g. crabs, lobsters, shrimps, krill or crayfish; Barnacles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/68—Protozoa, e.g. flagella, amoebas, sporozoans, plasmodium or toxoplasma
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system

Definitions

  • the present invention relates to a composition for softening muscles.
  • it is a composition for ingestion in order to increase the flexibility of skeletal muscle, which is said to affect motor function.
  • Muscle flexibility is an important factor for health promotion and injury prevention, and it is considered that sports injury can be prevented and reduced by maintaining and improving muscle flexibility (Non-Patent Document 1).
  • muscle flexibility and sports performance are also related, and it is known that running economy is improved by improving muscle flexibility by stretching (Non-patent Document 1). Therefore, it is considered that improving muscle flexibility leads to prevention / improvement of injury and improvement of exercise performance (Non-Patent Document 1).
  • Non-patent Document 2 Fish oil is rich in polyunsaturated fatty acids (hereinafter also referred to as PUFA) such as eicosapentaenoic acid (hereinafter also referred to as EPA) and docosahexaenoic acid (hereinafter also referred to as DHA).
  • PUFA polyunsaturated fatty acids
  • EPA eicosapentaenoic acid
  • DHA docosahexaenoic acid
  • the present invention focuses on muscle flexibility, which is attracting attention in the field of sports and geriatrics, and supports muscle flexibility by exercising and massage, etc. It is an object of the present invention to provide a composition that enhances the viscosity.
  • PUFA having a low viscosity is taken into the erythrocyte membrane, so that red blood cells become flexible and blood flow is smooth even in narrow blood vessels.
  • ingestion of PUFA would bring PUFA into skeletal muscle and improve skeletal muscle flexibility.
  • the flexibility of the skeletal muscle of rats fed with fish oil for several weeks was measured using a muscle hardness meter and rheometer. Confirmed and completed the present invention.
  • the gist of the present invention is the following composition (1) to (8) for softening muscles by oral ingestion.
  • composition according to (1) containing n-3 polyunsaturated fatty acids as refined fish oil, refined krill oil, and refined microbial oil.
  • FIG. 1 It is a figure which shows the shear strength of the anterior tibial muscle of the rat extract
  • FIG. It is a figure which shows the muscle hardness change rate of the rat thigh in Example 2.
  • FIG. It is a figure which shows the correlation with the shear strength of a rectus femoris muscle in the rat extract
  • PUFA is a fatty acid having 18 or more carbon atoms and 3 or more double bonds, preferably a fatty acid having 20 or more carbon atoms and 3 or more double bonds, more preferably 20 or more carbon atoms and a double bond. It is a fatty acid having 4 or more bonds.
  • n-3 PUFA include ⁇ -linolenic acid, eicosapentaenoic acid, docosapentaenoic acid, and docosahexaenoic acid.
  • the PUFA used in the present invention can be used in the form of glycerides or phospholipids containing free fatty acids, lower alcohol esters, or n-3 polyunsaturated fatty acids as constituent fatty acids.
  • esters with glycerin i.e. triglycerides, diglycerides, monoglycerides, or phospholipids, i.e. Or an ester with a lower alcohol (having 1 to 3 carbon atoms), that is, a methyl ester, an ethyl ester, or the like.
  • Preference is given to those containing n-3 fatty acids as the main component, such as EPA and DHA, and substantially free of n-6 fatty acids.
  • the total of n-6 fatty acids is 10% by weight or less, preferably 5% by weight or less.
  • triglycerides refined fish oil, refined microbial oil, or concentrated oil with a higher concentration of n-3 PUFA contained in them (enzyme reaction, chemical reaction to increase the concentration of n-3 PUFA in refined fish oil) Concentrated) can be used.
  • refined krill oil, refined microbial oil, etc. can be used as a phospholipid.
  • N-3 PUFA sources containing EPA and DHA include fish and shellfish extracts, animal extracts, egg yolk extracts, plant extracts, fungal extracts, etc., preferably krill oil, fish oil, squid extract, skipjack ovary extract Products, extracts of genetically modified plants, extracts of Labyrinthula, and the like.
  • Examples of the material containing a large amount of phospholipid include krill oil and squid extract.
  • the phospholipid concentration and purity in these materials can be arbitrarily adjusted by using techniques generally known in the art such as concentration, extraction, and / or purification, and blending.
  • EPA and / or DHA are known to be effective for hyperlipidemia and allergic symptoms, and many pharmaceuticals and various supplements are already on the market.
  • capsule preparations similar to these can be used. Specifically, a product obtained by processing a fat and oil obtained by adding an antioxidant to purified fish oil into a gelatin capsule is often used.
  • the dosage form of the preparation is not particularly limited as long as it is an orally administrable dosage form, and is a tablet, capsule (hard capsule, soft capsule), microcapsule, granule, fine granule, powder, oral liquid preparation (emulsion, Suspensions, etc.), syrups, jellies and the like.
  • a dosage form enclosed in a capsule particularly a soft capsule or a microcapsule is preferable.
  • Each formulation is prepared by methods known in the art, and usually used excipients, diluents, binders, wetting agents, disintegrants, disintegration inhibitors, absorption enhancers, lubricants, solubilizers, Prepared using buffers, emulsifiers, suspending agents and the like.
  • Additives include stabilizers, preservatives, buffers, isotonic agents, chelating agents, pH adjusters, surfactants, colorants, flavoring agents, flavoring agents, sweetening agents that are usually used depending on the dosage form. An agent or the like can be used.
  • the amount of n-3 PUFA contained in the preparation is, for example, 20% by weight or more, preferably 40% by weight or more, or 50% by weight or more, more preferably 80% by weight or more as the total amount of n-3 PUFA. is there.
  • any fish oil may be used as long as it contains EPA and DHA.
  • fish oils rich in EPA include sardine oil and cod liver oil
  • fish oils rich in DHA include tuna oil and bonito oil.
  • the concentrated oil of PUFA is a fat and oil in which the concentration of EPA / DHA in the triglyceride of refined fish oil is increased by using a lipase having regioselectivity and fatty acid selectivity.
  • n-3 PUFAs such as EPA and DHA are preferably taken orally in a total amount of 5 to 150 mg / kg per day. More preferably, it is 15 to 150 mg / kg, and particularly preferably 15 to 75 mg / kg. It may be taken at once or divided. It is preferable to ingest continuously, and the effect is recognized by continuous administration for at least 2 weeks.
  • n-3 PUFA is a food-derived ingredient, and since it has already been used for a long time in other applications, it can be safely consumed.
  • the use target is not particularly limited, and it can be used for subjects who want to soften muscles, from young people to elderly people. It is particularly preferable for those who perform sports or those who are concerned about muscle hardening due to age. It can also be applied to mammalian animals as objects of use. It is particularly preferable to use it for competition animals such as horses and dogs.
  • the composition of the present invention can be ingested as a food or together with a food ingredient because the active ingredient is extremely safe. Examples of the present invention will be described below, but the present invention is not limited thereto.
  • ⁇ Experiment method> 1 Experimental animals 7-week-old Wistar male rats were used as animals. The experiment was conducted after one week of pre-breeding. Rats were divided into 2 groups (6 groups), EPA / DHA-rich fish oil-added feed intake group (fish oil group) and lard-added feed intake group (Lard group). The feed was pair-feeded and the food intake was adjusted. Water was ad libitum. The animals were housed in individual cages made of stainless steel in a conditioned animal room with a room temperature of 22 ⁇ 2 ° C., 50 ⁇ 10% humidity, and illumination for 12 hours. 2.
  • Table 1 shows the fatty acid composition of the fish oil and lard used
  • Table 2 shows the composition of the AIN-93G modified feed.
  • the feeding period was 4 weeks. After the breeding period, the anterior tibial muscle (TA) was collected and stored frozen at ⁇ 80 ° C. until analysis.
  • TA anterior tibial muscle
  • Shear titration measurement The weight of the anterior tibial muscle was measured while cooling the sample stored at -80 ° C with liquid nitrogen. After the weight measurement, the sample was thawed for 24 hours in a low-temperature room in a tube. The moisture exuded from the thawed muscle tissue was wiped with a paper towel and weighed, and the shear strength was measured with a rheometer (RE-3305S, manufactured by YAMADEN, shear rate 1 mm / sec).
  • ⁇ Experiment method> Experimental animals Four-week-old Wistar male rats were used as animals. The experiment was conducted after one week of pre-breeding. Rats were divided into fish oil group or lard group (6 animals per group) and allowed to eat freely for 4 weeks. Water was ad libitum. The animals were housed in individual plastic plastic cages in an air-conditioned animal room with a room temperature of 22 ⁇ 2 ° C, 50 ⁇ 10% humidity, and illumination for 12 hours. 2.
  • soybean oil contained in AIN-93G is fish oil (fish oil produced by Nippon Suisan Co., Ltd., high content of EPA / DHA, 40% or more of total fatty acids) or lard ( AIN-93G modified feed of powder replaced with Oriental Yeast Co., Ltd.) was prepared.
  • a powder feed obtained by removing soybean oil from AIN-93G was obtained from Oriental Yeast Co., Ltd.
  • Table 3 shows the fatty acid composition of the fish oil used
  • Table 4 shows the component composition of the feed used. The same lard as in Table 1 was used.
  • the feeding period was 4 weeks. After the breeding period, the animals were dissected and the weight of each organ was measured and the shear strength of skeletal muscle was measured. In addition, during pre-breeding, thigh muscle hardness was measured at 2 weeks after the start of test feed intake and 4 weeks after the start of intake.
  • Shear strength measurement At the time of dissection, the anterior tibialis and rectus femoris were collected, the muscles were cut with a cutter with both ends fixed with two pins, and the shear strength at that time was measured with a rheometer (RE -3305S, manufactured by YAMADEN, shear rate 1 mm / sec).
  • Fig. 3 shows the correlation between rectus femoris shear strength and perirenal fat weight 4 weeks after the start of test feed intake.
  • composition of the present invention has the effect of softening muscles by oral administration, it can be used in the sports field and geriatric field by taking it as a pharmaceutical or a supplement.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Mycology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Emergency Medicine (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Microbiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Insects & Arthropods (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Nutrition Science (AREA)
  • Food Science & Technology (AREA)
  • Polymers & Plastics (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

L'invention concerne une composition qui améliore la souplesse des muscles par ingestion orale. La composition, qui assouplit les muscles par ingestion orale, comprend un acide gras n-3 hautement insaturé en tant que principe actif. L'acide gras n-3 hautement insaturé est de préférence sous la forme d'un acide gras libre, d'un ester d'alcool inférieur ou d'un glycéride ou d'un phospholipide contenant l'acide gras n-3 hautement insaturé en tant qu'acide gras constitutif. Des exemples particuliers correspondants comprennent l'acide eicosapentaénoïque, l'acide docosapentaénoïque, l'acide docosahexaénoïque, l'huile de poisson purifiée, l'huile de krill purifiée et l'huile microbienne purifiée.
PCT/JP2017/034436 2016-10-04 2017-09-25 Composition pour l'assouplissement des muscles WO2018066394A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2018543844A JPWO2018066394A1 (ja) 2016-10-04 2017-09-25 筋肉を柔軟にするための組成物

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2016196093 2016-10-04
JP2016-196093 2016-10-04

Publications (1)

Publication Number Publication Date
WO2018066394A1 true WO2018066394A1 (fr) 2018-04-12

Family

ID=61830929

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2017/034436 WO2018066394A1 (fr) 2016-10-04 2017-09-25 Composition pour l'assouplissement des muscles

Country Status (2)

Country Link
JP (1) JPWO2018066394A1 (fr)
WO (1) WO2018066394A1 (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113749255B (zh) * 2021-09-15 2022-11-29 江南大学 一种磷脂组合物在修复肌肉损伤的应用

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2004526458A (ja) * 2001-05-14 2004-09-02 マーテック・バイオサイエンシーズ・コーポレーション 飼鳥肉の風味、軟らかさ、および全消費者嗜好性の改善法
JP2005287376A (ja) * 2004-03-31 2005-10-20 Q P Corp 眼精疲労用飲食品組成物
JP2014515011A (ja) * 2011-03-18 2014-06-26 ネステク ソシエテ アノニム 加齢に伴う疾病を改善するのに有用な組成物及び方法

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2004526458A (ja) * 2001-05-14 2004-09-02 マーテック・バイオサイエンシーズ・コーポレーション 飼鳥肉の風味、軟らかさ、および全消費者嗜好性の改善法
JP2005287376A (ja) * 2004-03-31 2005-10-20 Q P Corp 眼精疲労用飲食品組成物
JP2014515011A (ja) * 2011-03-18 2014-06-26 ネステク ソシエテ アノニム 加齢に伴う疾病を改善するのに有用な組成物及び方法

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
KAWABATA, F. ET AL.: "Supplementation with eicosapentaenoic acid-rich fish oil improves exercise economy and reduces perceived exertion during submaximal steady-state exercise in normal healthy untrained men", BIOSCI. BIOTECHNOL. BIOCHEM., vol. 78, no. 12, 2014, pages 2081 - 2088, XP055398666, DOI: doi:10.1080/09168451.2014.946392 *
NORDEZ, A. ET AL.: "Assessment of muscle hardness changes induced by a submaximal fatiguing isometric contraction", J. ELECTROMYGOR. KINESIOL., vol. 19, no. 3, 2009, pages 484 - 491, XP026031590, DOI: doi:10.1016/j.jelekin.2007.11.005 *
PEOPLES, G. E. ET AL.: "Long-chain n-3 DHA reduces the extent of skeletal muscle fatigue in the rat in vivo hindlimb model", BR. J. NUTR., vol. III, no. 6, 2014, pages 996 - 1003 *
SIMOPOULOS, A. P.: "Omega-3 fatty acids and athletics", CURR. SPORTS MED. REP., vol. 6, no. 4, 2007, pages 230 - 236 *
SMITH, G. I. ET AL.: "Fish oil-derived n-3 PUFA therapy increases muscle mass and function in healthy older adults", AM. J. CLIN. NUTR., vol. 102, no. 1, 2015, pages 115 - 122, XP055398664, DOI: doi:10.3945/ajcn.114.105833 *
ZEBROWSKA, A. ET AL.: "Omega-3 fatty acids supplementation improves endothelial function and maximal oxygen uptake in endurance-trained athletes", EUR. J. SPORT SCI., vol. 15, no. 4, 2015, pages 305 - 314 *

Also Published As

Publication number Publication date
JPWO2018066394A1 (ja) 2019-10-03

Similar Documents

Publication Publication Date Title
Durmuş Fish oil for human health: omega-3 fatty acid profiles of marine seafood species
Youdim et al. Essential fatty acids and the brain: possible health implications
KR100895800B1 (ko) 피놀렌산의 용도
US20090099261A1 (en) Omega-3 mixtures
Asif Chemical characteristics and nutritional potentials of unsaturated fatty acids
JP2016185973A (ja) メタボリックシンドローム改善剤
CA2196880C (fr) Compositions a base d'acide nervonique
KR20010079724A (ko) 항 비만 및 내장축적지방 저감화기능을 보유하는 물질, 및그 용도
Daidj et al. Hepatoprotective and anti-obesity properties of sardine by-product oil in rats fed a high-fat diet
JP5547486B2 (ja) セサミン類とアラキドン酸類を含有する組成物
WO2018066394A1 (fr) Composition pour l'assouplissement des muscles
Keten Review on the beneficial effects of omega-3 enriched eggs by dietary flaxseed oil supplementation
JPH0336493B2 (fr)
Gillingham The metabolic fate of alpha linolenic acid (ALA)
JPH0759540A (ja) アラキドン酸含有健康食品
US20080146664A1 (en) Method for treating diseases caused by accumulation of body fat
Mu Bioavailability of omega-3 long-chain polyunsaturated fatty acids from foods
Bhat Functional lipids as nutraceuticals: A review
Behera Dietary fish oil concentrates associated health benefits: A recent development of cardiovascular risk reduction
Lala et al. Challenge with fumonisin FB1+ FB2 alters profile of fatty acids in Nile tilapia fingerlings
Morales et al. Lipids from marine sources
JP2006282644A (ja) 疲労回復剤
US11266665B1 (en) Omega-3 fatty acid nutriceutical compositions and methods
WO2024009986A1 (fr) Agent améliorant l'endurance
WO2021065659A1 (fr) Composition pour améliorer la fonction intestinale par régulation de d'expression de l'aquaporine 3, et son utilisation

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 17858233

Country of ref document: EP

Kind code of ref document: A1

ENP Entry into the national phase

Ref document number: 2018543844

Country of ref document: JP

Kind code of ref document: A

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 17858233

Country of ref document: EP

Kind code of ref document: A1